New obesity drug shows promise in early safety trial
NCT ID NCT06557356
First seen Nov 20, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This early-stage study tested a new drug called LY3532226 in 132 people with obesity to see if it is safe and how the body processes it. Participants received weekly or monthly doses for up to 20 weeks. The goal was to check for side effects and measure drug levels in the blood, not to prove weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
-
Fortrea Clinical Research Unit
Madison, Wisconsin, 53704, United States
-
Lilly Centre for Clinical Pharmacology
Singapore, 138623, Singapore
Conditions
Explore the condition pages connected to this study.